الفهرس 
Breast cancer overviewOnly 14 pages are availabe for public view
 |  | from | 205 |  |  |
| | | from | 205 | | |
Abstract
Breast cancer is the most common cancer among women and its incidence is increasing worldwide. Breast cancer comprises a remarkably diverse group of diseases in terms of presentation, morphology, biologic characteristics and clinical behavior.Triple negative breast cancer (TNBC) has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared to other subgroups of breast cancer. TNBC is primarily, but not exclusively, comprised of a molecularly distinct subtype of breast cancer, the basal-like subtype. The molecular biology and pathophysiology of TNBC is incompletely understood but it is improving rapidly with the advent of molecular biology platforms. Moreover, the established risk factors for breast cancer as a whole may not apply to this unique subgroup of patients. Finally, since TNBC is defined by the absence of a target, there are currently limitations to employing a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of TNBC in order to improve prevention, optimize conventional agents, and unveil novel therapeutic targets.